The beneficial effects of Xolair® (Omalizumab) as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available treatment (GINA 2002 step IV - The Israeli arm of the INNOVATE study

Zev M. Sthoeger, Abraham Eliraz, Ilan Asher, Neville Berkman, Daniel Elbirt*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

13 Scopus citations

Fingerprint

Dive into the research topics of 'The beneficial effects of Xolair® (Omalizumab) as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available treatment (GINA 2002 step IV - The Israeli arm of the INNOVATE study'. Together they form a unique fingerprint.

Medicine & Life Sciences